METTL3 and metabolic dysfunction-associated steatotic liver disease: Consistently, METTL3 knockout inhibited NAFLD-HCC development, as shown by reduced AFP and MRI measurements (Figure 3G) and the reduced tumor number (p = 0.019) and size (p = 0.042) at sacrifice (Figures 3H and S3G).